Unknown

Dataset Information

0

Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma.


ABSTRACT: Variants in the cytochrome P450 2C9 (CYP2C9) gene are associated with impaired metabolism of celecoxib. We examined the influence of CYP2C9*2 (R144C) and CYP2C9*3 (I359L) variants on dose-related response or toxicity in a randomized trial of celecoxib.We identified individuals with CYP2C9*2 and CYP2C9*3 genotypes (>or=1 variant allele) in the Adenoma Prevention with Celecoxib trial. Following adenoma removal, patients were assigned randomly to groups given placebo or low-dose (200 mg twice daily) or high-dose (400 mg twice daily) celecoxib and underwent follow-up colonoscopies at 1 and/or 3 years.Among 1660 patients, 21% were CYP2C9*2, and 12% were CYP2C9*3 genotypes. Overall, celecoxib was associated with a dose-dependent reduction in adenoma, compared with placebo, with relative risks (RR) of 0.65 (95% confidence interval [CI]: 0.56-0.76) for the low-dose and 0.54 (95% CI: 0.46-0.63) for the high-dose groups. However, the additional protective effect of the high dose, compared with the low-dose, was observed only in those with CYP2C9*3 genotypes (RR, 0.51; 95% CI: 0.30-0.87). The high dose, compared with low dose, was not associated with significant risk reduction among those with CYP2C9*2 (RR, 0.83; 95% CI: 0.57-1.21) or wild-type (RR, 0.89; 95% CI: 0.72-1.11) genotypes. Compared with placebo, a higher incidence of cardiovascular events was associated with both doses among patients with wild-type genotypes but only with the high dose among patients with variant genotypes.The greater efficacy of high-dose celecoxib, compared with the low-dose, in preventing colorectal adenoma appears confined to individuals with slow metabolizer (CYP2C9*3) genotypes. Genetic variability influences susceptibility to the potential benefits and hazards of celecoxib.

SUBMITTER: Chan AT 

PROVIDER: S-EPMC2693443 | biostudies-literature | 2009 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma.

Chan Andrew T AT   Zauber Ann G AG   Hsu Meier M   Breazna Aurora A   Hunter David J DJ   Rosenstein Rebecca B RB   Eagle Craig J CJ   Hawk Ernest T ET   Bertagnolli Monica M MM  

Gastroenterology 20090221 7


<h4>Background & aims</h4>Variants in the cytochrome P450 2C9 (CYP2C9) gene are associated with impaired metabolism of celecoxib. We examined the influence of CYP2C9*2 (R144C) and CYP2C9*3 (I359L) variants on dose-related response or toxicity in a randomized trial of celecoxib.<h4>Methods</h4>We identified individuals with CYP2C9*2 and CYP2C9*3 genotypes (>or=1 variant allele) in the Adenoma Prevention with Celecoxib trial. Following adenoma removal, patients were assigned randomly to groups giv  ...[more]

Similar Datasets

| S-EPMC3201766 | biostudies-literature
| S-EPMC3252487 | biostudies-literature
| S-EPMC4037290 | biostudies-literature
| S-EPMC2990920 | biostudies-literature
| S-EPMC6824622 | biostudies-literature
| S-EPMC3618415 | biostudies-literature
| S-EPMC4723878 | biostudies-literature
| S-EPMC3154944 | biostudies-literature
| S-EPMC8820617 | biostudies-literature
| S-EPMC5761073 | biostudies-literature